On April 23, 2025 Parabilis Medicines (formerly Fog Pharmaceuticals), a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer, reported the presentation of preclinical data on its first-in-class targeted protein degrader of ERG at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, being held April 25–30, 2025, in Chicago, Illinois (Press release, Parabilis Medicines, APR 23, 2025, View Source [SID1234652083]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The transcription factor ERG has been a long-recognized high-value target in prostate cancer, where ERG fusions have been implicated in 40-50% of all cases. Despite its relevance, ERG has remained undrugged by conventional inhibitors or first-generation degraders because the protein lacks small molecule binding pockets.

Parabilis’s ERG degrader overcomes this challenge by using the company’s proprietary Helicon peptide technology, which enables intracellular targeting of "flat" protein surfaces. The company’s prostate cancer franchise also includes a selective degrader of androgen receptor (AR) targeting a site outside the canonical androgen-binding site on the protein, thereby addressing a common resistance mechanism that arises in response to AR antagonist therapies. Together Parabilis’s degraders of ERG and AR could potentially provide meaningful and differentiated therapeutic approaches to treat patients with metastatic castrate-resistant prostate cancer (mCRPC).

Full details of the poster are as follows:

Title: "Degradation of the ETS transcription factor ERG by stabilized helical peptide (Helicon) degraders enables pharmacological validation in ERG-fusion prostate cancer models"
Abstract Number: 4246/3
Presentation Date and Time: Tuesday, April 29, 9:00 a.m. – 12:00 p.m. CDT
Session: New and Emerging Cancer Drug Targets
Location: Poster Section 17